Kentaro Okamoto

Dr. Kentaro Okamoto

Pediatrics, Ehime prefectural Imabari hospital
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
HNHisahide Nishio
Hisahide Nishio
ENEmma Niba
Emma Niba
TSToshio Saito
Toshio Saito
KOKentaro Okamoto
Kentaro Okamoto
YTYASUHIRO TAKESHIMA
YASUHIRO TAKESHIMA
HAHiroyuki Awano
Hiroyuki Awano
Spinal muscular atrophy (SMA) is a lower motor neuron disease with autosomal recessive inheritance. The first cases of SMA were reported by Werdnig in 1891. Although the phenotypic variation of SMA led to controversy regarding the clinical entity of the disease, the genetic homogeneity of SMA was proved in 1990. Five years later, in 1995, the gene responsible for SMA, SMN1, was identified. Genetic testing of SMN1 has enabled precise epidemiological studies, revealing that SMA occurs in 1 of 10,000 to 20,000 live births and that more than 95% of affected patients are homozygous for SMN1 deletion. In 2016, nusinersen was the first drug approved for treatment of SMA in the United States. Two other drugs were subsequently approved: onasemnogene abeparvovec and risdiplam. Clinical trials with these drugs targeting patients with pre-symptomatic SMA (those who were diagnosed by genetic testing but showed no symptoms) revealed that such patients could achieve the milestones of independent sitting and/or walking. Following the great success of these trials, population-based newborn screening programs for SMA (more precisely, SMN1-deleted SMA) have been increasingly implemented worldwide. Early detection by newborn screening and early treatment with new drugs are expected to soon become the standards in the field of SMA.

1 February 2021 in Brain and Development
Verified
Journal Article
Closed access
ENEmma Niba
Emma Niba
HNHisahide Nishio
Hisahide Nishio
yogik onky silvana wijayayogik onky silvana wijaya
yogik onky silvana wijaya
PLPoh San Lai
Poh San Lai
TTTakenori Tozawa
Takenori Tozawa
MSMasakazu Shinohara
Masakazu Shinohara

Verified
Journal Article
Open access
PDF file
TKTomokazu Kimizu
Tomokazu Kimizu
SIShinobu Ida
Shinobu Ida
KOKentaro Okamoto
Kentaro Okamoto
HAHiroyuki Awano
Hiroyuki Awano
ENEmma Niba
Emma Niba
MSMasakazu Shinohara
Masakazu Shinohara
Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder that causes degeneration of anterior horn cells in the human spinal cord and subsequent loss of motor neurons. The severe form of SMA is among the genetic diseases with the highest infant mortality. Although SMA has been considered incurable, newly developed drugs—nusinersen and onasemnogene abeparvovec—improve the life prognoses and motor functions of affected infants. To maximize the efficacy of these drugs, treatments should be started at the pre-symptomatic stage of SMA. Thus, newborn screening for SMA is now strongly recommended. Herein, we provide some data based on our experience of SMA diagnosis by genetic testing in Japan. A total of 515 patients suspected of having SMA or another lower motor neuron disease were tested. Among these patients, 228 were diagnosed as having SMA with survival motor neuron 1 (SMN1) deletion. We analyzed the distribution of clinical subtypes and ages at genetic testing in the SMN1-deleted patients, and estimated the SMA incidence based on data from Osaka and Hyogo prefectures, Japan. Our data showed that confirmed diagnosis by genetic testing was notably delayed, and the estimated incidence was 1 in 30,000–40,000 live births, which seemed notably lower than in other countries. These findings suggest that many diagnosis-delayed or undiagnosed cases may be present in Japan. To prevent this, newborn screening programs for SMA (SMA-NBS) need to be implemented in all Japanese prefectures. In this article, we also introduce our pilot study for SMA-NBS in Osaka Prefecture.

1 August 2021 in Brain and Development
Verified
Journal Article
Closed access
yogik onky silvana wijayayogik onky silvana wijaya
yogik onky silvana wijaya
MRMawaddah Ar Rohmah
Mawaddah Ar Rohmah
ENEmma Niba
Emma Niba
NMNaoya Morisada
Naoya Morisada
YNYoriko Noguchi
Yoriko Noguchi
MSMasakazu Shinohara
Masakazu Shinohara

14 November 2022 in Genes
Verified
Journal Article
Open access
PDF file
YNYoriko Noguchi
Yoriko Noguchi
RBRyosuke Bo
Ryosuke Bo
HNHisahide Nishio
Hisahide Nishio
HMHisayuki Matsumoto
Hisayuki Matsumoto
KMKeiji Matsui
Keiji Matsui
HAHiroyuki Awano
Hiroyuki Awano
Spinal muscular atrophy (SMA) is a common devastating neuromuscular disorder, usually involving homozygous deletion of the SMN1 gene. Newly developed drugs can improve the motor functions of infants with SMA when treated in the early stage. To ensure early diagnosis, newborn screening for SMA (SMA-NBS) via PCR-based genetic testing with dried blood spots (DBSs) has been spreading throughout Japan. In Hyogo Prefecture, we performed a pilot study of SMA-NBS to assess newborn infants who underwent routine newborn metabolic screening between February 2021 and August 2022. Hyogo Prefecture has ~40,000 live births per year and the estimated incidence of SMA is 1 in 20,000–25,000 based on genetic testing of symptomatic patients with SMA. Here, we screened 8336 newborns and 12 screen-positive cases were detected by real-time PCR assay. Multiplex ligation-dependent probe amplification assay excluded ten false positives and identified two patients. These false positives might be related to the use of heparinized and/or diluted blood in the DBS sample. Both patients carried two copies of SMN2, one was asymptomatic and the other was symptomatic at the time of diagnosis. SMA-NBS enables us to prevent delayed diagnosis of SMA, even if it does not always allow treatment in the pre-symptomatic stage.

30 September 2024 in Genes
Verified
Journal Article
Open access
PDF file
HNHisahide Nishio
Hisahide Nishio
ENEmma Niba
Emma Niba
TSToshio Saito
Toshio Saito
KOKentaro Okamoto
Kentaro Okamoto
TLTomoko Lee
Tomoko Lee
PLPoh San Lai
Poh San Lai
Background: Spinal muscular atrophy (SMA) is a genetic disease characterized by loss of motor neurons in the spinal cord and lower brainstem. The term “SMA” usually refers to the most common form, 5q-SMA, which is caused by biallelic mutations in SMN1 (located on chromosome 5q13). However, long before the discovery of SMN1, it was known that other forms of SMA existed. Therefore, SMA is currently divided into two groups: 5q-SMA and non-5q-SMA. This is a simple and practical classification, and therapeutic drugs have only been developed for 5q-SMA (nusinersen, onasemnogene abeparvovec, risdiplam) and not for non-5q-SMA disease. Methods: We conducted a non-systematic critical review to identify the characteristics of each SMA disease. Results: Many of the non-5q-SMA diseases have similar symptoms, making DNA analysis of patients essential for accurate diagnosis. Currently, genetic analysis technology using next-generation sequencers is rapidly advancing, opening up the possibility of elucidating the pathology and treating non-5q-SMA. Conclusion: Based on accurate diagnosis and a deeper understanding of the pathology of each disease, treatments for non-5q-SMA diseases may be developed in the near future.